Syndicate Bio, a biotech platform company that is advancing genomics and precision medicine initiatives across the globe, has announced its strategic partnership with the National Institute for Cancer Research and Treatment (NICRAT), to bridge cancer disparity gaps in Nigeria.
Through the “Cancer Genome Nigeria” project, the two firms aimed at bridging cancer disparity gaps by studying the most prevalent cancers across Nigeria’s six geopolitical zones with over 300 ethnolinguistic groups.
Ene-Obong disclosed that Syndicate Bio’s approach forges collaborative engagement with existing healthcare systems and stakeholders as a means to drive local impact across Africa and inclusive advancements in global genomics.
The biotech company is leveraging collaborations with governments, pharmaceutical companies, academia and other key industry stakeholders to deepen local precision medicine impact while generating invaluable datasets that improve global health outcomes and accelerates drug discovery and development, the founder stated.
